DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library provides 2,320 clinically approved, well-characterized bioactive compounds for high-throughput and high-content screening applications (ApexBio). The library supports rapid drug repositioning and pharmacological target identification by covering diverse mechanisms of action, including enzyme inhibition, receptor modulation, and signal pathway regulation (Andi et al., 2022). Compounds are delivered as 10 mM DMSO solutions in various formats, ensuring stability and reproducibility under -20°C or -80°C conditions. Representative drugs such as doxorubicin, metformin, and atorvastatin enable mechanistic interrogation across oncology, neurodegeneration, and infectious disease models. This resource integrates seamlessly into HTS/HCS workflows, expediting translational research and novel therapeutic discovery.

Biological Rationale

Drug repositioning leverages existing clinically approved molecules to discover new indications or therapeutic targets, reducing development time and cost (Andi et al., 2022). The DiscoveryProbe™ FDA-approved Drug Library (L1021) includes compounds approved by the FDA, EMA, HMA, CFDA, and PMDA, ensuring broad pharmacological relevance and regulatory validation. These compounds have established safety profiles and pharmacokinetics, making them ideal candidates for high-throughput screening in disease models such as cancer, neurodegenerative disorders, and viral infections. The diversity of compound classes facilitates interrogation of cellular pathways (e.g., kinases, GPCRs, ion channels) and identification of new drug-target interactions. Drug libraries like DiscoveryProbe™ accelerate the identification of actionable hits, enabling efficient translation from bench to clinic (related article).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library is composed of small molecules with diverse mechanisms of action, allowing systematic exploration of biological pathways. Key categories include:

• Receptor agonists and antagonists: Targeting GPCRs, nuclear hormone receptors, and tyrosine kinase receptors to modulate signaling cascades.
• Enzyme inhibitors: Including kinase inhibitors, protease inhibitors (such as HCV NS3/4A inhibitors), and metabolic enzyme modulators (Andi et al., 2022).
• Ion channel modulators: Affecting voltage-gated or ligand-gated channels critical for neuronal and cardiac function.
• Signal pathway regulators: Compounds that intervene in Wnt, MAPK, PI3K/AKT, and other key cellular pathways.

For example, remdesivir, originally developed for hepatitis C and Ebola, was repurposed as an RNA-dependent RNA polymerase (RdRp) inhibitor for SARS-CoV-2 (Andi et al., 2022). The library's inclusion of such compounds underpins its utility for identifying new indications and mechanisms.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 unique compounds, each validated by at least one major regulatory agency or pharmacopeia (product page).
• Compounds are provided as 10 mM solutions in DMSO, stable for 12 months at -20°C and up to 24 months at -80°C, enabling reproducible HTS/HCS workflows (ApexBio, link).
• Hepatitis C NS3/4A protease inhibitors (e.g., boceprevir, telaprevir) in the library covalently bind the SARS-CoV-2 main protease (Mpro), as evidenced by crystallographic and biochemical assays (Andi et al., 2022).
• Remdesivir, present in the library, was the first FDA-approved small molecule inhibitor for SARS-CoV-2 RNA-dependent RNA polymerase, validating the value of drug repurposing strategies (Andi et al., 2022).
• High-throughput and high-content screening with DiscoveryProbe™ accelerates the identification of candidate compounds for cancer and neurodegenerative disease models (related article).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is designed for a variety of research and preclinical applications:

• Drug Repositioning Screening: Rapidly screen approved compounds for new indications, shortening development timelines (Andi et al., 2022).
• Pharmacological Target Identification: Map compound-target interactions using phenotypic or target-based assays (article; this piece provides updated, mechanistic integration with recent viral target studies).
• Cancer Research Drug Screening: Identify novel therapeutics or combinatorial regimens using clinically validated compounds (article; here, we add data on infectious disease models).
• Neurodegenerative Disease Drug Discovery: Use compounds with known blood-brain barrier penetration and CNS activity to interrogate neuroepigenetic pathways (article; this article extends the discussion to enzyme and protease inhibitors).
• Signal Pathway Regulation: Dissect cellular signaling networks by targeting kinases, phosphatases, or transcriptional regulators.
• Enzyme Inhibitor Screening: Evaluate inhibitors against proteases, kinases, and metabolic enzymes implicated in disease.

Common Pitfalls or Misconceptions

• Not All Compounds Are Suitable for In Vivo Studies: While all compounds are clinically approved, some may have poor bioavailability or off-target toxicity in specific models.
• Library Is Not a Replacement for Primary Screening in Non-Human Species: The library is optimized for human targets and may not reflect cross-species pharmacology.
• Compounds Are Not Guaranteed to Be Active in Every Disease Context: Activity is context-dependent; negative results should be interpreted with caution.
• High-Throughput Does Not Eliminate Need for Orthogonal Validation: Hits require secondary validation to confirm specificity and mechanism.
• Stability Is Temperature- and Solvent-Dependent: Deviations from recommended storage (-20°C or -80°C in DMSO) may compromise compound integrity and reproducibility.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is provided in ready-to-use 10 mM DMSO solutions, compatible with automated liquid handling systems. Formats include 96-well microplates, deep well plates, and 2D barcoded screw-top tubes, facilitating integration into both high-throughput (HTS) and high-content (HCS) screening platforms. Recommended storage is -20°C for up to 12 months or -80°C for up to 24 months to ensure compound stability. Shipping is performed on blue ice for evaluation samples, with options for room temperature or blue ice for bulk orders. Data management is streamlined by 2D barcoding, enabling traceable screening and downstream analysis. The library can be combined with phenotypic assays, target-based screens, and omics-based readouts for comprehensive pharmacological profiling. For detailed deployment workflows and translational strategies, see Translational Breakthroughs with the DiscoveryProbe™ FDA-approved Drug Library (this article incorporates recent viral benchmarking data).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a robust, verifiable resource for high-throughput drug repositioning and target identification. Its diverse compound coverage, regulatory validation, and workflow compatibility accelerate translational research across oncology, neurodegeneration, and infectious diseases. Recent crystallographic and biochemical studies demonstrate its effectiveness for rapid antiviral discovery (e.g., SARS-CoV-2 protease inhibitors). Adoption of this library enables reproducible, scalable, and mechanistically informed screening, supporting the next generation of therapeutic breakthroughs. Further integration with omics and AI-driven analytics will expand its impact in precision medicine. For detailed specifications and ordering, visit the DiscoveryProbe™ FDA-approved Drug Library product page.